InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Sweetleaf Free
04/25/24 1:25 PM
profile icon
Sweetleaf Free
04/15/24 7:55 AM
profile icon
Sweetleaf Free
04/12/24 8:39 AM
profile icon
Sweetleaf Free
04/11/24 8:44 AM
profile icon
Sweetleaf Free
04/08/24 1:57 PM
profile icon
Blueheel1 Free
04/08/24 12:23 PM
profile icon
Sweetleaf Free
04/08/24 9:01 AM
profile icon
Sweetleaf Free
04/08/24 8:38 AM
profile icon
Awl416 Free
04/08/24 8:33 AM
profile icon
Sweetleaf Free
04/05/24 2:52 PM
profile icon
Sweetleaf Free
04/02/24 8:38 AM
profile icon
Sweetleaf Free
03/28/24 11:41 AM
profile icon
Sweetleaf Free
03/20/24 11:30 AM
profile icon
Sweetleaf Free
03/19/24 3:59 PM
profile icon
Sweetleaf Free
03/18/24 1:24 PM
profile icon
Sweetleaf Free
03/15/24 9:46 AM
profile icon
Sweetleaf Free
03/14/24 10:20 AM
profile icon
Sweetleaf Free
03/14/24 9:44 AM
profile icon
Sweetleaf Free
03/14/24 9:33 AM
profile icon
fung_derf Grandfathered
03/11/24 2:53 PM
profile icon
fung_derf Grandfathered
03/11/24 2:41 PM
profile icon
fung_derf Grandfathered
03/11/24 2:37 PM
profile icon
Monroe1 Free
03/11/24 2:31 PM
Bullish
Bullish
profile icon
Monroe1 Free
03/11/24 2:21 PM
Bullish
Bullish
profile icon
Monroe1 Free
03/11/24 2:08 PM
profile icon
Sweetleaf Free
03/11/24 9:35 AM
profile icon
Sweetleaf Free
03/11/24 8:44 AM
profile icon
Sweetleaf Free
03/10/24 5:30 PM
profile icon
fung_derf Grandfathered
03/08/24 11:43 AM
profile icon
fung_derf Grandfathered
03/08/24 11:31 AM
profile icon
fung_derf Grandfathered
03/08/24 11:26 AM
profile icon
Monroe1 Free
03/08/24 10:58 AM
profile icon
fung_derf Grandfathered
03/08/24 9:52 AM
profile icon
Monroe1 Free
03/07/24 7:38 PM
profile icon
fung_derf Grandfathered
03/07/24 3:25 PM
profile icon
Monroe1 Free
03/07/24 2:43 PM
profile icon
Sweetleaf Free
03/04/24 9:20 PM
profile icon
Blueheel1 Free
03/04/24 7:36 PM
profile icon
Sweetleaf Free
03/02/24 7:08 PM
profile icon
Sweetleaf Free
03/02/24 10:41 AM
profile icon
Sweetleaf Free
02/14/24 12:47 PM
profile icon
Sweetleaf Free
02/14/24 12:47 PM
profile icon
Sweetleaf Free
02/07/24 1:30 PM
profile icon
Sweetleaf Free
02/06/24 1:46 PM

RenovoRx Inc (RNXT) RSS Feed

Followers
6
Posters
29
Posts (Today)
0
Posts (Total)
188
Created
08/31/21
Type
Free
Moderators
RenovoRx Logo
NASDAQ Capital MarketRNXT
Company Website: https://renovorx.com/


About RenovoRx, Inc.

RenovoRx is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. We are committed to developing transformative therapies for improved quality of life and extended life in cancer patients.

 
 

Delivering Therapy Where it Matters

Developing Innovative Combination Therapies for Targeted Treatment of Difficult-to-Access Cancers

 
 
 

Standard of Care Pancreatic Cancer Treatment May be Ineffective for Treating Tumors and is Often Accompanied by Debilitating Side Effects

The Phase III TIGeR-PaC clinical trial is an ongoing randomized multi-center study using RenovoRx’s innovative therapy platform, Trans-Arterial Micro-Perfusion (TAMP™), to evaluate RenovoRx’s first product candidate, RenovoGem™. The study is evaluating trans-arterial delivery, a form of intra-arterial administration, of an FDA-approved chemotherapy, gemcitabine, to treat LAPC following stereotactic body radiation therapy (SBRT). The study is comparing treatment of gemcitabine with TAMP versus systemic IV administration of gemcitabine and nab-paclitaxel.

 
 

TAMP: Trans-Arterial Micro-Perfusion Therapy Platform

RenovoRx’s proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic (intravenous (IV) therapy). RenovoRx’s unique approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate, RenovoGem, a novel oncology drug-device combination product, is being investigated under a US IND that is regulated by FDA 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research (the drug division of FDA.)

RenovoGem will also be evaluated as a potential therapy in bile duct cancer, with a Phase III clinical trial expected to begin in late 2023 with other potential pipeline indication opportunities to follow including non-small cell lung cancer, uterine tumors, glioblastoma, and sarcoma. RenovoGem received FDA Orphan Drug Designation for pancreatic cancer and bile duct cancer which provides 7 years of market exclusivity upon NDA approval.

 

RenovoRx Catheter Illustration
 
 
 

RenovoRx today announced the appointment of Michel Ducreux, M.D., Ph.D., Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board
at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI., to the Company’s Scientific Advisory Board (SAB).
 

July 20, 2023

Logo - imugene
RenovoRx and Imugene Ltd today announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.

June 29, 2023

RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

Older couple hugging
RenovoRx today presented new positive data on progression-free survival (PFS) from the pivotal Phase III open label TIGeR-PaC study of RenovoGem (intra-arterial administration of gemcitabine) in locally advanced pancreatic cancer 

  Watch RenovoTAMP™: Trans-Arterial Micro-Perfusion Therapy Platform
on
#YouTube
 
https://www.youtube.com/watch?v=EyNichBRudk&t=9s

 
 Watch “About RenovoTAMP Therapy Platform.mp4”
on
 
#Vimeo

https://vimeo.com/722650426?ref=tw-share
 

DISCLAIMER:

Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here.  

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post